China’s Luoyang Huizhong Biotech Co. Ltd. has invested CNY150 million (US$24.5 million) to build six new vaccine production lines in the Luolong High Tech Industry Development Zone.
The production lines include a 100m mL capacity line for inactivated vero cell vaccines; a 200m dose capacity line for live vero cell vaccines; a 300m mL capacity line for inactivated poultry tissue vaccines; a 2bn dose capacity line for live poultry tissue vaccines; a 100m mL capacity line for inactivated bacterial vaccines; and a 100m dose capacity line for live bacterial vaccines, according a to report provided by Smart Agriculture Analytics.
Other facilities included in the company’s investment include a liquid and solid disinfectant workshop and warehouse, and a quality inspection center.
Luoyong Huizhong Biotech is involved in the research and production of new vaccines for veterinary use. It is a wholly owned subsidiary and private high-tech joint stock enterprise of Pulike Biological Engineering Inc. The company, according to its website, was founded in July 2011.